|

Ifinatamab Deruxtecan Clinical Trials

7 actively recruiting trials across 7 locations

Also known as: DS-7300a, I-DXd, I-DXd, MK-2400, DS-7300a, MK-2400

Birmingham, Alabama1 trial

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

University of Alabama -Birmingham

Phase 1/2

Phoenix, Arizona1 trial

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

Mayo Clinic in Arizona - Phoenix ( Site 0044)

Phase 3

Springdale, Arkansas1 trial

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Highlands Oncology Group

Phase 3

Fullerton, California1 trial

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

Providence Medical Foundation

Phase 3

Los Angeles, California1 trial

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

Los Angeles Cancer Network

Phase 2

Washington D.C., District of Columbia1 trial

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

MedStar Georgetown Cancer Institute at MedStar Washington Hospital Center ( Site 0026)

Phase 1/2

Lexington, Kentucky1 trial

A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)

University of Kentucky Chandler Medical Center ( Site 0019)

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.